The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study

Idasanutlin, an MDM2 antagonist, showed clinical activity and a rapid reduction in JAK2 V617F allele burden in patients with polycythemia vera (PV) in a phase 1 study. This open-label phase 2 study evaluated idasanutlin in patients with hydroxyurea (HU)-resistant/-intolerant PV, per the European Leu...

Descripción completa

Detalles Bibliográficos
Autores principales: Mascarenhas, John, Passamonti, Francesco, Burbury, Kate, El-Galaly, Tarec Christoffer, Gerds, Aaron, Gupta, Vikas, Higgins, Brian, Wonde, Kathrin, Jamois, Candice, Kovic, Bruno, Huw, Ling-Yuh, Katakam, Sudhakar, Maffioli, Margherita, Mesa, Ruben, Palmer, Jeanne, Bellini, Marta, Ross, David M., Vannucchi, Alessandro M., Yacoub, Abdulraheem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864654/
https://www.ncbi.nlm.nih.gov/pubmed/34933330
http://dx.doi.org/10.1182/bloodadvances.2021006043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864654/
https://www.ncbi.nlm.nih.gov/pubmed/34933330
http://dx.doi.org/10.1182/bloodadvances.2021006043

Ejemplares similares